Closes #892 (#893)

* Updates to czi_drsm dataset

* Updates to czi_drsm dataset

* Running all tests

* Updating documentation

bigbio/hub/hub_repos/czi_drsm/README.md

@@ -0,0 +1,68 @@
+---
+language:
+  - en 
+bigbio_language:
+  - English
+license: Creative Commons Zero v1.0 Universal
+bigbio_license_shortname: cc0-1.0
+multilinguality: monolingual
+pretty_name: CZI DRSM
+homepage: https://github.com/chanzuckerberg/DRSM-corpus
+bigbio_pubmed: false
+bigbio_public: true
+bigbio_tasks:
+  - TXTCLASS
+---
+
+# Dataset Card for CZI DRSM
+
+## Dataset Description
+
+- **Homepage:** https://github.com/chanzuckerberg/DRSM-corpus
+- **Pubmed:** False
+- **Public:** True
+- **Tasks:** TXTCLASS
+
+Research Article document classification dataset based on aspects of disease research. Currently, the dataset consists of three subsets: 
+
+(A) classifies title/abstracts of papers into most popular subtypes of clinical, basic, and translational papers (~20k papers); 
+    - Clinical Characteristics, Disease Pathology, and Diagnosis - 
+        Text that describes (A) symptoms, signs, or ‘phenotype’ of a disease; 
+        (B) the effects of the disease on patient organs, tissues, or cells; 
+        (C) the results of clinical tests that reveal pathology (including
+        biomarkers); (D) research that use this information to figure out
+        a diagnosis.
+    - Therapeutics in the clinic - 
+        Text describing how treatments work in the clinic (but not in a clinical trial).
+    - Disease mechanism - 
+        Text that describes either (A) mechanistic involvement of specific genes in disease 
+        (deletions, gain of function, etc); (B) how molecular signalling or metabolism 
+        binding, activating, phosphorylation, concentration increase, etc.) 
+        are involved in the mechanism of a disease; or (C) the physiological 
+        mechanism of disease at the level of tissues, organs, and body systems.
+    - Patient-Based Therapeutics - 
+        Text describing (A) Clinical trials (studies of therapeutic measures being 
+        used on patients in a clinical trial); (B) Post Marketing Drug Surveillance 
+        (effects of a drug after approval in the general population or as part of 
+        ‘standard healthcare’); (C) Drug repurposing (how a drug that has been 
+        approved for one use is being applied to a new disease).
+
+(B) identifies whether a title/abstract of a paper describes substantive research into Quality of Life (~10k papers); 
+    - -1 - the paper is not a primary experimental study in rare disease
+    - 0 - the study does not directly investigate quality of life
+    - 1 - the study investigates qol but not as its primary contribution
+    - 2 - the study's primary contribution centers on quality of life measures
+
+(C) identifies if a paper is a natural history study (~10k papers). 
+   - -1 - the paper is not a primary experimental study in rare disease
+    - 0 - the study is not directly investigating the natural history of a disease
+    - 1 - the study includes some elements a natural history but not as its primary contribution
+    - 2 - the study's primary contribution centers on observing the time course of a rare disease
+
+These classifications are particularly relevant in rare disease research, a field that is generally understudied.
+
+## Citation Information
+
+```
+# N/A
+```